Extracellular Vesicles from Adipose-Derived Mesenchymal Stem Cells Combined with PEG Hydrogel Alleviate Maternal Simulated Birth Injury in a Rat Model.
Wang Q., Li Y., Zhang Y., Wu X., Wang S., Sun X.
Prospective Study, published in Adv Healthc Mater (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Adv Healthc Mater (2025)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40237194
- DOI
- 10.1002/adhm.202405259
Abstract (original English)
Pelvic organ prolapse (POP) is a common and distressing condition affecting women, particularly those with a history of vaginal delivery. The impact of extracellular vesicles derived from adipose-derived mesenchymal stem cells (ADSC-EVs) on pelvic floor tissue injury remains unclear. Due to their short half-life and rapid clearance in vivo, ADSC-EVs lose efficacy quickly. To address this, an injectable tetra-PEG hydrogel to encapsulate ADSC-EVs (PEG@EVs) is developed. The hydrogel is formed by tetra-PEG-NH 2 and tetra-PEG-NHS through an ammonolysis reaction, leading to the formation of amide bonds within seconds. Vaginal wall tissue from POP patients shows disruption in the extracellular matrix, lipid peroxidation, and inflammation. In vitro, ADSC-EVs significantly reduce H₂O₂-induced oxidative stress, lipid oxidation, and apoptosis, while enhancing the expression of Nrf2 and its downstream targets-CAT, NQO1, HO-1, and SOD2. ADSC-EVs also upregulate GPX4 and SLC7A11, reducing mitochondrial damage and mitigating ferroptosis. The Nrf2 inhibitor ML385 reverses these protective effects. In a rat model of childbirth injury, PEG@EVs treatment promotes Nrf2 nuclear translocation, induces the M1-to-M2 macrophage conversion, reduces inflammation, and stimulates collagen deposition, thereby accelerating vaginal wall repair. The findings of this study may serve as a foundation for early t
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.